Company Overview

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious neurologically mediated conditions with significant unmet medical needs. The company’s primary focus is the development of nalbuphine extended-release formulations designed to treat chronic cough disorders and pruritic conditions. Trevi operates within the biotechnology and specialty pharmaceutical industries, with research and development activities centered on neuromodulation pathways involving opioid receptor activity.

The company’s lead product candidate is Haduvio™, an oral extended-release formulation of nalbuphine. Trevi has primarily concentrated development efforts on chronic cough indications, including refractory chronic cough and idiopathic pulmonary fibrosis-related chronic cough, while also evaluating applications in prurigo nodularis and other chronic pruritic conditions. Trevi’s strategic positioning is based on leveraging a mechanism that acts as both a kappa opioid receptor agonist and a mu opioid receptor antagonist, which the company believes may provide therapeutic benefit while limiting certain risks associated with traditional opioids. Trevi Therapeutics was founded in 2011 and is headquartered in Connecticut. The company became publicly traded on Nasdaq under the ticker TRVI following its merger with an existing public entity in 2019.

Business Operations

Trevi Therapeutics operates primarily as a single-segment clinical-stage biotechnology company focused on drug development rather than commercial pharmaceutical sales. Revenue generation has historically been limited, with operations funded primarily through equity offerings, public market financing, and cash reserves rather than product commercialization. The company’s principal operational activities include clinical trial execution, regulatory engagement, intellectual property management, and pharmaceutical development associated with Haduvio™.

The company’s operational footprint is concentrated in the United States, though clinical development activities have involved international trial sites and collaborations with contract research organizations and manufacturing partners. Trevi relies on third-party manufacturers and development partners for production and clinical supply functions rather than owning large-scale manufacturing infrastructure. Its key controlled assets include proprietary formulations, clinical data, patents, and intellectual property surrounding nalbuphine extended-release technologies. Public filings indicate that the company has maintained relationships with external clinical and manufacturing organizations to support development programs.

Strategic Position & Investments

Trevi Therapeutics’ strategy is centered on advancing Haduvio™ through late-stage clinical development for chronic cough-related conditions and expanding potential indications where centrally mediated sensory symptoms are involved. The company has prioritized chronic cough markets due to limited approved therapies and growing clinical recognition of unmet patient demand. Clinical studies and regulatory interactions have been focused on establishing efficacy and safety profiles that could support future commercialization opportunities.

The company’s investments have primarily been directed toward research and development, including Phase 2 and Phase 3 clinical programs, regulatory preparation, and intellectual property protection. Unlike diversified pharmaceutical companies, Trevi does not maintain a broad portfolio of commercial subsidiaries or large acquisition activity. Its value proposition is concentrated around a single lead asset platform. Public disclosures also indicate continued evaluation of additional therapeutic applications involving chronic pruritus and neurologic symptom modulation, reflecting a targeted rather than diversified development approach.

Geographic Footprint

Trevi Therapeutics is headquartered in New Haven, Connecticut, and its core corporate operations are based in the United States. The company’s principal market focus is North America, particularly the U.S. pharmaceutical and biotechnology sector, where it conducts regulatory interactions with the U.S. Food and Drug Administration and manages most corporate functions.

Although Trevi does not currently maintain a broad commercial international footprint, its clinical development activities have included engagement with research institutions, investigators, and service providers across multiple regions. The company’s operational influence is primarily tied to global clinical development infrastructure rather than direct commercial operations in foreign markets. As a clinical-stage organization, its geographic reach is narrower than that of multinational pharmaceutical companies, though future commercialization strategies could involve broader international partnerships.

Leadership & Governance

Trevi Therapeutics was co-founded by pharmaceutical industry executives and scientists with experience in specialty therapeutics and central nervous system drug development. The company’s leadership strategy has emphasized disciplined clinical execution, targeted indication selection, and capital-efficient development focused on high unmet medical need categories.

Key executives and leadership include:

• Jennifer Good – President and Chief Executive Officer
• Barry Shin – Chief Financial Officer
• Mitchell Steiner, M.D. – Chairman of the Board
• David Clark, Ph.D. – Senior Vice President, Pharmaceutical Development
• Julie B. Krop, M.D. – Chief Medical Officer

Public company filings and investor materials describe leadership’s strategic vision as focused on advancing differentiated therapies for chronic neurologic and sensory disorders while maintaining operational flexibility typical of development-stage biotechnology companies. Governance oversight is provided through a board structure consistent with Nasdaq-listed biotechnology firms, with committees overseeing audit, compensation, and corporate governance functions.